A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update DOI Creative Commons
Gabriel Samaşcă, Claudia Burz,

Irena Pintea

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 17(9), С. 1121 - 1121

Опубликована: Авг. 24, 2024

Researchers have performed numerous studies on immunotherapy because of the high death rate associated with gastric cancer (GC). GC research has made tremendous progress, and we wanted to provide an update this topic. On basis update, suggest performing a new medical evaluation before initiating in patients increase success immunotherapies. We propose that start immunotherapy, they should be evaluated given score one two points for following factors: immunopathological features, molecular genomic potential consequences bacterial pathogens, immunotherapeutic resistance hyperprogressive illness, use biomarkers gauge their prognosis responses optimize surgery. The proposed scoring system could also help diagnosis GC. With all advances genetics, immunology, microbiology, improved, not changed. Currently, diagnosed undergo surgical resection as only permanent solution. Patients who meet maximum from presented proposal eligible immediately after immunotherapy. Therefore, first-line option clinicians.

Язык: Английский

The role of Prolyl 3-Hydroxylase 1 (P3H1) in tumor development and prognosis: a pan-cancer analysis with validation in colonic adenocarcinoma DOI
Yanqin Chen, Moazzam Ali, Muhammad Tayyab

и другие.

American Journal of Translational Research, Год журнала: 2025, Номер 17(2), С. 770 - 790

Опубликована: Янв. 1, 2025

Cancer is a multifaceted disease characterized by unregulated cell proliferation, evasion of apoptosis, and metastasis. Recent studies have highlighted the importance extracellular matrix remodeling post-translational modifications in tumorigenesis. Prolyl 3-hydroxylase 1 (P3H1), an enzyme involved collagen hydroxylation, has gained attention for its role cancer progression. This study investigates P3H1 expression, prognostic value, functional relevance across multiple human cancers using combination bioinformatic experimental approaches. Using The Genome Atlas (TCGA) data from TIMER2.0 UALCAN databases, we observed significant upregulation mRNA protein various cancers. Prognostic analysis GEPIA2 KM plotter revealed that high expression correlates with poorer overall survival colon adenocarcinoma (COAD), kidney renal clear carcinoma (KIRC), liver hepatocellular (LIHC). Further, genetic promoter methylation analyses showed low mutation frequencies reduced specific types. Functional pathway enrichment indicated formation, endoplasmic reticulum activity, pathways such as ECM-receptor interaction PI3K-Akt signaling. Validation linked immunosorbent assay COAD patient serum samples demonstrated significantly elevated levels compared to healthy controls, AUC approaching 1.0 receiver operating characteristic (ROC) curve analysis. suggests potential diagnostic biomarker. Additionally, experiments were conducted cells assess P3H1's Knockdown HCT116 resulted reduction colony migratory abilities these cells. These findings emphasize COAD, KIRC, LIHC pathogenesis possible utility clinical diagnosis.

Язык: Английский

Процитировано

0

STX1A regulates ferroptosis and chemoresistance in gastric cancer through mitochondrial function modulation DOI
Yan Niu, Chunyu Liu, Lizhou Jia

и другие.

Human Cell, Год журнала: 2025, Номер 38(3)

Опубликована: Март 8, 2025

Язык: Английский

Процитировано

0

Epigenetic Regulation of DNA Methylation and RNA Interference in Gastric Cancer: A 2024 Update DOI Creative Commons

Iulia Lupan,

Vasile Bințințan, Diana Deleanu

и другие.

Biomedicines, Год журнала: 2024, Номер 12(9), С. 2001 - 2001

Опубликована: Сен. 3, 2024

Gastric cancer (GC) remains a significant public health concern because of its lethality, underscoring the need for deeper insights into molecular mechanisms. Recent studies have increasingly highlighted role epigenetic modifications as critical players in progression. Despite their importance, research specifically addressing factors GC is relatively scarce. This paper seeks to bridge that gap by examining recent literature elucidates landscape associated with GC. The investigation long noncoding RNAs (lncRNAs) has revealed substantial involvement gene dysregulation and alterations within tumors. Notably, lncRNAs such LINC00853 LINC01266 been identified contributors modulation expression. Furthermore, overexpression

Язык: Английский

Процитировано

1

Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma DOI Creative Commons
Zhongyi Zhang, Mei Zhao, Zubing Zhou

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Окт. 18, 2024

Objectives The role of matrix metalloproteinases (MMPs) in Skin Cutaneous Melanoma (SKCM) development and progression is unclear so far. This comprehensive study delved into the intricate MMPs SKCM progression. Methods RT-qPCR, bisulfite sequencing, WES analyzed MMP gene expression, promoter methylation, mutations cell lines. TCGA datasets validated findings. DrugBank molecular docking identified potential regulatory drugs, line experiments confirmed key genes tumorigenesis. Results Our findings unveiled significant up-regulation MMP9, MMP12, MMP14, MMP16, coupled with hypomethylation their promoters lines, implicating involvement disease Mutational analysis highlighted a low frequency these genes, indicating less expression mechanisms. Prognostic assessments showcased correlation between elevated poor overall survival (OS) patients. Additionally, functional involving silencing revealed impact on cellular proliferation, further emphasizing significance MMP16 pathobiology. Conclusion identifies Estradiol Calcitriol as drugs for modulating SKCM, highlighting diagnostic prognostic biomarkers.

Язык: Английский

Процитировано

1

A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update DOI Creative Commons
Gabriel Samaşcă, Claudia Burz,

Irena Pintea

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 17(9), С. 1121 - 1121

Опубликована: Авг. 24, 2024

Researchers have performed numerous studies on immunotherapy because of the high death rate associated with gastric cancer (GC). GC research has made tremendous progress, and we wanted to provide an update this topic. On basis update, suggest performing a new medical evaluation before initiating in patients increase success immunotherapies. We propose that start immunotherapy, they should be evaluated given score one two points for following factors: immunopathological features, molecular genomic potential consequences bacterial pathogens, immunotherapeutic resistance hyperprogressive illness, use biomarkers gauge their prognosis responses optimize surgery. The proposed scoring system could also help diagnosis GC. With all advances genetics, immunology, microbiology, improved, not changed. Currently, diagnosed undergo surgical resection as only permanent solution. Patients who meet maximum from presented proposal eligible immediately after immunotherapy. Therefore, first-line option clinicians.

Язык: Английский

Процитировано

0